Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.
15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval .
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics MarketThe global focal segmentmental glomerulosclerosis (FSGS) treatments market sales is expected to expand at a compound annual growth rate (CAGR) of 5% between 2023 and 2033, from US$ 3 billion in 2023 to US$ 4.89 billion by 2033. From 2018 to 2022, Focal Seg.
Industrial Starches Market Insights - 2024, Growth Prospects, openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.